Metabolic changes in the plasma of mild Alzheimer’s disease patients treated with Hachimijiogan

Background: Alzheimer’s disease (AD), the most prevalent form of dementia, is a debilitating, progressive neurodegeneration. Amino acids play a wide variety of physiological and pathophysiological roles in the nervous system, and their levels and disorders related to their synthesis have been related to cognitive impairment, the core feature of AD. Our previous multicenter trial showed that hachimijiogan (HJG), a traditional Japanese herbal medicine (Kampo), has an adjuvant effect for Acetylcholine estelase inhibitors (AChEIs) and that it delays the deterioration of the cognitive dysfunction of female patients with mild AD. However, there are aspects of the molecular mechanism(s) by which HJG improves cognitive dysfunction that remain unclear. Objectives: To elucidate through metabolomic analysis the mechanism(s) of HJG for mild AD based on changes in plasma metabolites. Methods: Sixty-seven patients with mild AD were randomly assigned to either an HJG group taking HJG extract 7.5 g/day in addition to AChEI or to a control group treated only with AChEI (HJG:33, Control:34). Blood samples were collected before, 3 months, and 6 months after the first drug administration. Comprehensive metabolomic analyses of plasma samples were done by optimized LC-MS/MS and GC-MS/MS methods. The web-based software MetaboAnalyst 5.0 was used for partial least square-discriminant analysis (PLS-DA) to visualize and compare the dynamics of changes in the concentrations of the identified metabolites. Results: The VIP (Variable Importance in Projection) score of the PLS-DA analysis of female participants revealed a significantly higher increase in plasma metabolite levels after HJG administration for 6 months than was seen in the control group. In univariate analysis, the aspartic acid level of female participants showed a significantly higher increase from baseline after HJG administration for 6 months when compared with the control group. Conclusion: Aspartic acid was a major contributor to the difference between the female HJG and control group participants of this study. Several metabolites were shown to be related to the mechanism of HJG effectiveness for mild AD.

[1]  Michio Suzuki,et al.  An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer’s disease , 2022, Frontiers in Pharmacology.

[2]  T. Ohmori,et al.  Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer’s disease (from the Nakayama Study) , 2022, Scientific Reports.

[3]  Y. Liu,et al.  Activating transcription factor 6 regulates cystathionine to increase autophagy and restore memory in Alzheimer' s disease model mice. , 2022, Biochemical and biophysical research communications.

[4]  K. Nagashima,et al.  Effectiveness and safety of kamikihito, a traditional Japanese medicine, in managing anxiety among female patients with intractable chronic constipation. , 2021, Complementary therapies in clinical practice.

[5]  M. Nagino,et al.  Comprehensive metabolome analysis for the pharmacological action of inchinkoto, a hepatoprotective herbal medicine , 2021, Metabolomics.

[6]  B. Dunn,et al.  Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective. , 2021, JAMA internal medicine.

[7]  M. Mintun,et al.  Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.

[8]  Guowang Xu,et al.  Alteration of Metabolic Profile and Potential Biomarkers in the Plasma of Alzheimer’s Disease , 2020, Aging and disease.

[9]  Cheng Guo,et al.  Association Between Peripheral Adiponectin and Lipids Levels and the Therapeutic Response to Donepezil Treatment in Han Chinese Patients With Alzheimer’s Disease , 2020, Frontiers in Aging Neuroscience.

[10]  Fan Wang,et al.  High-Throughput Metabolomics for Discovering Potential Biomarkers and Identifying Metabolic Mechanisms in Aging and Alzheimer’s Disease , 2020, Frontiers in Cell and Developmental Biology.

[11]  S. Danti,et al.  Daily functioning and dementia , 2020, Dementia & neuropsychologia.

[12]  D. Bennett,et al.  Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis , 2019, Neurobiology of Aging.

[13]  H. Lane,et al.  D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer's disease or mild cognitive impairment , 2019, Pharmacology Biochemistry and Behavior.

[14]  D. Hervás,et al.  Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker. , 2019, Journal of proteomics.

[15]  Eun Ji Song,et al.  Traditional Oriental Medicines and Alzheimer’s Disease , 2019, Aging and disease.

[16]  T. Yen,et al.  A metabolomic approach to identifying biomarkers in blood of Alzheimer's disease , 2019, Annals of clinical and translational neurology.

[17]  A. Nishi,et al.  Data on metabolic profiling of healthy human subjects’ plasma before and after administration of the Japanese Kampo medicine maoto , 2018, Data in brief.

[18]  R. Suzuki,et al.  Change in Amino Acid Pools During Neuronal Differentiation of PC12 Cells , 2018, In Vivo.

[19]  David M. Shade,et al.  Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer’s Disease , 2018, American journal of Alzheimer's disease and other dementias.

[20]  H. Nakae,et al.  Kampo Medicines for Frailty in Locomotor Disease , 2018, Front. Nutr..

[21]  M. Mintun,et al.  Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.

[22]  J. Wilkins,et al.  Application of Metabolomics in Alzheimer’s Disease , 2018, Front. Neurol..

[23]  Qiong Yang,et al.  Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study , 2017, Alzheimer's & Dementia.

[24]  M. Kainuma,et al.  The Traditional Japanese Herbal Medicine Hachimijiogan Elicits Neurite Outgrowth Effects in PC12 Cells and Improves Cognitive in AD Model Rats via Phosphorylation of CREB , 2017, Front. Pharmacol..

[25]  M. Kainuma,et al.  Effect of hachimijiogan on memory impairment induced by beta‐amyloid combined with cerebral ischemia in rats , 2017 .

[26]  M. Mielke,et al.  Recent advances in the application of metabolomics to Alzheimer's Disease. , 2014, Biochimica et biophysica acta.

[27]  Andre Altmann,et al.  Sex modifies the APOE‐related risk of developing Alzheimer disease , 2014, Annals of neurology.

[28]  H. Soininen,et al.  Metabolome in progression to Alzheimer's disease , 2011, Translational Psychiatry.

[29]  J. Garcia-Fernández,et al.  D‐Aspartic acid is a novel endogenous neurotransmitter , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  G. Fisher,et al.  Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients , 2005, Neuroscience Letters.

[31]  J. Lindon,et al.  Metabonomics: a platform for studying drug toxicity and gene function , 2002, Nature Reviews Drug Discovery.

[32]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[33]  Kun Xie,et al.  High-Throughput Metabolomics for Discovering Potential Biomarkers and Identifying Metabolic Mechanisms in Aging and Alzheimer’s Disease , 2020 .

[34]  C. Antunez,et al.  A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.